QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

23,585 signal articles · 328 in last 24h · 112,405 total before filter · latest 39m ago
328last 24h
2141last 7d
379● bullish (7d)
188● bearish (7d)
204publishers
AllMacro296Earnings1216M&A91Regulatory23Product13Analyst20
✕ clear all filtersticker: IEXsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More
24/7 Wall St.21h agoneutral
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More

With CPI dropping at 8:30 AM and the Strait of Hormuz near shutdown, Wall Street faces a pivotal morning that could swing stocks sharply in either direction, and analysts at Deutsche Bank, Oppenheimer, Berenberg, and others are already repositioning ahead of the numbers.

IDEX Q2 Earnings Call Highlights
MarketBeat14d agoneutral
IDEX Q2 Earnings Call Highlights

IDEX (NYSE:IEX) reported second-quarter 2026 results that exceeded its expectations, supported by growth in its Health & Science Technologies segment, stronger orders and operational execution. The company raised its full-year outlook for organic sales growth, adjusted EBITDA margin and adjusted

IDEX Q1 Earnings Call Highlights
MarketBeat104d agoneutral
IDEX Q1 Earnings Call Highlights

IDEX (NYSE:IEX) reported first-quarter 2026 results that management said came in above expectations, supported by growth in its targeted “advantage markets” and continued application of the company’s 80/20 operating philosophy. Quarterly performance and orders President and CEO Eric Ashleman said I

IDEX (IEX) Q1 2026 Earnings Call Transcript
Motley Fool105d agoneutral
IDEX (IEX) Q1 2026 Earnings Call Transcript

IDEX delivered a strong first quarter and continue to see our growth strategies gain traction as we expand and integrate capabilities in targeted advantaged markets powered by 8020. In the first quarter, IDEX delivered organic sales growth of 5% and adjusted EBITDA margin of 26%, which reflects a margin expansion of 50 basis points year-over-year. Strength was most pronounced in our Health & Science Technologies, or HST segment, where secular drivers continue to fuel growth across high-value applications in data center, semiconductor and space and defense markets.